Pharmaceuticals
AstraZeneca rejects Pfizer’s revised $106 billion offer
02 May 2014
Today’s 50 pounds ($84.47) a share indicative offer followed AstraZeneca's decision to reject an earlier proposal that valued it at 46.61 pounds per share
AstraZeneca to consider Pfizer’s $106-bn bid
02 May 2014
The announcement comes just days after AstraZeneca Plc denied plans to discuss any partnership proposals with Pfizer
Bayer offers to swap cash and animal health unit for Merck's consumer healthcare
30 Apr 2014
German healthcare major Bayer AG has offered to swap its animal health unit and also pay some cash in exchange for Merck & Co's consumer healthcare business
HC blocks Ranbaxy-Sun Pharma merger over insider trading allegations
30 Apr 2014
The order was in response to a petition for a Sebi inquiry into possible insider trading in Ranbaxy shares that saw heavy trading before the merger with Sun Pharma was announced
Reckitt Benckiser confirms bidding for Merck & Co's consumer health business
29 Apr 2014
British consumer goods company Reckitt Benckiser has emerged as a front runner in the auction, although Bayer AG, Novartis, and Procter & Gamble Co are also in the race
Pfizer confirms AstraZeneca's rejection; to explore options
28 Apr 2014
US drugs giant Pfizer today confirmed that it had made a $98.67 billion (£58.73 billion) takeover offer for AstraZeneca, which was rejected by the UK-based company
Forest Labs to buy GI specialist Furiex in $1.46-bn deal
28 Apr 2014
Forest, which itself is in the process of being acquired by Actavis Plc for $25 billion, said that Actavis supported the deal
.webp)
.webp)
